CHIA-CHI LINCHIH-HSIN YANG2020-05-262020-05-2620091776-2596https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349151088&doi=10.1007%2fs11523-009-0104-2&partnerID=40&md5=12d29d4b1b7bc63af1b7fe4b16fdbb82https://scholars.lib.ntu.edu.tw/handle/123456789/495104Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC. Several phase II trials have been conducted utilizing EGFR TKIs in elderly or poor performance status patients with advanced NSCLC. This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC. ? 2009 Springer-Verlag.[SDGs]SDG34 [3 chloro 4 (2 pyridinylmethoxy)anilino] 3 cyano 6 (4 dimethylaminocrotonamido) 7 ethoxyquinoline; 6 [4 (4 ethyl 1 piperazinylmethyl)phenyl] 4 (alpha methylbenzylamino) 7h pyrrolo[2,3 d]pyrimidine; antineoplastic metal complex; BIBW 2992; canertinib; carboplatin; docetaxel; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; gemcitabine; navelbine; paclitaxel; pelitinib; pf 00299804; placebo; taxane derivative; unclassified drug; vandetanib; xl 647; alopecia; anemia; anorexia; bacterial pneumonia; cancer chemotherapy; cancer patient; chemotherapy induced emesis; chronic obstructive lung disease; clinical trial; deep vein thrombosis; diarrhea; drug fatality; fatigue; febrile neutropenia; hematuria; human; lung adenocarcinoma; lung alveolus cell carcinoma; lung non small cell cancer; monotherapy; multiple cycle treatment; neutropenia; overall survival; peripheral neuropathy; priority journal; prognosis; quality of life; rash; review; skin toxicity; unspecified side effect; Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Receptor, Epidermal Growth Factor; Treatment OutcomeReview10.1007/s11523-009-0104-2193433002-s2.0-67349151088